Furthermore, accumulating evidence suggests that increased BDNF signaling could improve cognition in Alzheimer’s disease [12, 15], indicating that positive modulation of NGF and BDNF signaling may be a relevant strategy to develop new treatment options for Alzheimer’s disease and other conditions where cognition is impaired. This evidence concerns the gene NGF and early-onset autosomal dominant Alzheimer disease.